Tak Paul Peterinsider trades
In SEC Form 4 filings, Tak Paul Peter is listed as Chief Executive Officer of Candel Therapeutics, Inc. (CADL). In the last 90 days, Tak Paul Peter sold $3.16M of Candel Therapeutics, Inc. (CADL) on the open market and bought none. All 2 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| CADLCandel Therapeutics, Inc. | Chief Executive Officer | 4 | Sep 11 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-11
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| CADLCandel Therapeutics, Inc. | Sep 11 | Sep 11 | S | 59,379 | $10.46 | Sale −$620,891 | 113,321 | Yes | Form 4 |
| CADLCandel Therapeutics, Inc. | Sep 10 | Sep 11 | M | 125,000 | $1.55 | $193,750 | 393,566 | Yes | Form 4 |
| CADLCandel Therapeutics, Inc. | Sep 10 | Sep 11 | S | 220,866 | $11.50 | Sale −$2,539,893 | 172,700 | Yes | Form 4 |
| CADLCandel Therapeutics, Inc. | Sep 10 | Sep 11 | M · derivative | 125,000 | $1.55 | $193,750 | 1,638,968 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.